Visual Outcomes in Presumed Congenital Foveal Toxoplasmosis
Congenital macular lesions attributed to toxoplasmosis may limit potential visual acuity. The appearance and location of these scars may cause physicians to overlook associated amblyopia. This study reviews the visual outcomes and benefits of amblyopia therapy in children with foveal toxoplasmosis s...
Gespeichert in:
Veröffentlicht in: | American journal of ophthalmology 2020-06, Vol.214, p.9-13 |
---|---|
Hauptverfasser: | , , , |
Format: | Artikel |
Sprache: | eng |
Schlagworte: | |
Online-Zugang: | Volltext |
Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
container_end_page | 13 |
---|---|
container_issue | |
container_start_page | 9 |
container_title | American journal of ophthalmology |
container_volume | 214 |
creator | Reynolds, Margaret M.M. Chisholm, Smith Ann M. Schroeder, Richard Lueder, Gregg T. |
description | Congenital macular lesions attributed to toxoplasmosis may limit potential visual acuity. The appearance and location of these scars may cause physicians to overlook associated amblyopia. This study reviews the visual outcomes and benefits of amblyopia therapy in children with foveal toxoplasmosis scars.
Retrospective observational case series.
Setting: Single center. Patient Population: Children with presumed foveal toxoplasmosis scars who underwent amblyopia treatment. Main Outcome Measure: Charts were reviewed for amblyopia treatment, fundus photographs, optical coherence tomography (OCT), and visual acuity.
Median age at presentation was 2.8 years and median follow-up was 6.2 years. Occlusion therapy was undertaken in 9 patients. Median duration of occlusion therapy was 1.7 years. Six patients improved with occlusion therapy (average 4.6 lines gained on optotype acuity). Final visual acuity ranged from 20/25 to 20/250, with 6 of 8 patients better than 20/80. OCT confirmed macular scars in 5 patients, with varying degrees of foveal architecture disruption.
Despite the striking appearance of the lesions in patients with presumed foveal toxoplasmosis, visual potential may be better than expected. The appearance of the lesions is not always predictive of visual outcome. A trial of occlusion therapy to treat amblyopia should be initiated in these patients to ensure that they reach their maximal visual potential. |
doi_str_mv | 10.1016/j.ajo.2020.01.034 |
format | Article |
fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2353007757</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0002939420300520</els_id><sourcerecordid>2353007757</sourcerecordid><originalsourceid>FETCH-LOGICAL-c381t-53c9e86d30da508a8cf540c6a4c1d8a8a961e54b5cf5d1bcdb43472f9d67d4cc3</originalsourceid><addsrcrecordid>eNp9kE1LxDAQhoMoun78AC-y4MVL66RJ2hRPsvgFC-tBvYZsMispbbMm7aL_3siqBw-ehpl55mV4CDmlkFOg5WWT68bnBRSQA82B8R0yobKqMypruksmAFBkNav5ATmMsUltWfFqnxywApiQDCbk6sXFUbfTxTgY32Gcun76GDCOHdrpzPev2Lsh7W_9BlN58u9-3erY-ejiMdlb6TbiyXc9Is-3N0-z-2y-uHuYXc8zwyQdMsFMjbK0DKwWILU0K8HBlJobalOr65Ki4EuR5pYujV1yxqtiVduystwYdkQutrnr4N9GjIPqXDTYtrpHP0ZVMMEAqkpUCT3_gzZ-DH36ThW8EKXkNZOJolvKBB9jwJVaB9fp8KEoqC-zqlHJrPoyq4CqZDbdnH0nj8vk5vfiR2UCrrYAJhUbh0FF47A3aF1AMyjr3T_xn5I4iC0</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2425684938</pqid></control><display><type>article</type><title>Visual Outcomes in Presumed Congenital Foveal Toxoplasmosis</title><source>Access via ScienceDirect (Elsevier)</source><creator>Reynolds, Margaret M.M. ; Chisholm, Smith Ann M. ; Schroeder, Richard ; Lueder, Gregg T.</creator><creatorcontrib>Reynolds, Margaret M.M. ; Chisholm, Smith Ann M. ; Schroeder, Richard ; Lueder, Gregg T.</creatorcontrib><description>Congenital macular lesions attributed to toxoplasmosis may limit potential visual acuity. The appearance and location of these scars may cause physicians to overlook associated amblyopia. This study reviews the visual outcomes and benefits of amblyopia therapy in children with foveal toxoplasmosis scars.
Retrospective observational case series.
Setting: Single center. Patient Population: Children with presumed foveal toxoplasmosis scars who underwent amblyopia treatment. Main Outcome Measure: Charts were reviewed for amblyopia treatment, fundus photographs, optical coherence tomography (OCT), and visual acuity.
Median age at presentation was 2.8 years and median follow-up was 6.2 years. Occlusion therapy was undertaken in 9 patients. Median duration of occlusion therapy was 1.7 years. Six patients improved with occlusion therapy (average 4.6 lines gained on optotype acuity). Final visual acuity ranged from 20/25 to 20/250, with 6 of 8 patients better than 20/80. OCT confirmed macular scars in 5 patients, with varying degrees of foveal architecture disruption.
Despite the striking appearance of the lesions in patients with presumed foveal toxoplasmosis, visual potential may be better than expected. The appearance of the lesions is not always predictive of visual outcome. A trial of occlusion therapy to treat amblyopia should be initiated in these patients to ensure that they reach their maximal visual potential.</description><identifier>ISSN: 0002-9394</identifier><identifier>EISSN: 1879-1891</identifier><identifier>DOI: 10.1016/j.ajo.2020.01.034</identifier><identifier>PMID: 32035830</identifier><language>eng</language><publisher>United States: Elsevier Inc</publisher><subject>Age ; Antibiotics ; Children & youth ; Congenital diseases ; Patients ; Strabismus ; Surgery ; Toxoplasmosis ; Visual impairment</subject><ispartof>American journal of ophthalmology, 2020-06, Vol.214, p.9-13</ispartof><rights>2020 Elsevier Inc.</rights><rights>Copyright © 2020. Published by Elsevier Inc.</rights><rights>2020. Elsevier Inc.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c381t-53c9e86d30da508a8cf540c6a4c1d8a8a961e54b5cf5d1bcdb43472f9d67d4cc3</citedby><cites>FETCH-LOGICAL-c381t-53c9e86d30da508a8cf540c6a4c1d8a8a961e54b5cf5d1bcdb43472f9d67d4cc3</cites></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://dx.doi.org/10.1016/j.ajo.2020.01.034$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,780,784,3550,27924,27925,45995</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/32035830$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Reynolds, Margaret M.M.</creatorcontrib><creatorcontrib>Chisholm, Smith Ann M.</creatorcontrib><creatorcontrib>Schroeder, Richard</creatorcontrib><creatorcontrib>Lueder, Gregg T.</creatorcontrib><title>Visual Outcomes in Presumed Congenital Foveal Toxoplasmosis</title><title>American journal of ophthalmology</title><addtitle>Am J Ophthalmol</addtitle><description>Congenital macular lesions attributed to toxoplasmosis may limit potential visual acuity. The appearance and location of these scars may cause physicians to overlook associated amblyopia. This study reviews the visual outcomes and benefits of amblyopia therapy in children with foveal toxoplasmosis scars.
Retrospective observational case series.
Setting: Single center. Patient Population: Children with presumed foveal toxoplasmosis scars who underwent amblyopia treatment. Main Outcome Measure: Charts were reviewed for amblyopia treatment, fundus photographs, optical coherence tomography (OCT), and visual acuity.
Median age at presentation was 2.8 years and median follow-up was 6.2 years. Occlusion therapy was undertaken in 9 patients. Median duration of occlusion therapy was 1.7 years. Six patients improved with occlusion therapy (average 4.6 lines gained on optotype acuity). Final visual acuity ranged from 20/25 to 20/250, with 6 of 8 patients better than 20/80. OCT confirmed macular scars in 5 patients, with varying degrees of foveal architecture disruption.
Despite the striking appearance of the lesions in patients with presumed foveal toxoplasmosis, visual potential may be better than expected. The appearance of the lesions is not always predictive of visual outcome. A trial of occlusion therapy to treat amblyopia should be initiated in these patients to ensure that they reach their maximal visual potential.</description><subject>Age</subject><subject>Antibiotics</subject><subject>Children & youth</subject><subject>Congenital diseases</subject><subject>Patients</subject><subject>Strabismus</subject><subject>Surgery</subject><subject>Toxoplasmosis</subject><subject>Visual impairment</subject><issn>0002-9394</issn><issn>1879-1891</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><recordid>eNp9kE1LxDAQhoMoun78AC-y4MVL66RJ2hRPsvgFC-tBvYZsMispbbMm7aL_3siqBw-ehpl55mV4CDmlkFOg5WWT68bnBRSQA82B8R0yobKqMypruksmAFBkNav5ATmMsUltWfFqnxywApiQDCbk6sXFUbfTxTgY32Gcun76GDCOHdrpzPev2Lsh7W_9BlN58u9-3erY-ejiMdlb6TbiyXc9Is-3N0-z-2y-uHuYXc8zwyQdMsFMjbK0DKwWILU0K8HBlJobalOr65Ki4EuR5pYujV1yxqtiVduystwYdkQutrnr4N9GjIPqXDTYtrpHP0ZVMMEAqkpUCT3_gzZ-DH36ThW8EKXkNZOJolvKBB9jwJVaB9fp8KEoqC-zqlHJrPoyq4CqZDbdnH0nj8vk5vfiR2UCrrYAJhUbh0FF47A3aF1AMyjr3T_xn5I4iC0</recordid><startdate>20200601</startdate><enddate>20200601</enddate><creator>Reynolds, Margaret M.M.</creator><creator>Chisholm, Smith Ann M.</creator><creator>Schroeder, Richard</creator><creator>Lueder, Gregg T.</creator><general>Elsevier Inc</general><general>Elsevier Limited</general><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>K9.</scope><scope>NAPCQ</scope><scope>7X8</scope></search><sort><creationdate>20200601</creationdate><title>Visual Outcomes in Presumed Congenital Foveal Toxoplasmosis</title><author>Reynolds, Margaret M.M. ; Chisholm, Smith Ann M. ; Schroeder, Richard ; Lueder, Gregg T.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c381t-53c9e86d30da508a8cf540c6a4c1d8a8a961e54b5cf5d1bcdb43472f9d67d4cc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Age</topic><topic>Antibiotics</topic><topic>Children & youth</topic><topic>Congenital diseases</topic><topic>Patients</topic><topic>Strabismus</topic><topic>Surgery</topic><topic>Toxoplasmosis</topic><topic>Visual impairment</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Reynolds, Margaret M.M.</creatorcontrib><creatorcontrib>Chisholm, Smith Ann M.</creatorcontrib><creatorcontrib>Schroeder, Richard</creatorcontrib><creatorcontrib>Lueder, Gregg T.</creatorcontrib><collection>PubMed</collection><collection>CrossRef</collection><collection>ProQuest Health & Medical Complete (Alumni)</collection><collection>Nursing & Allied Health Premium</collection><collection>MEDLINE - Academic</collection><jtitle>American journal of ophthalmology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Reynolds, Margaret M.M.</au><au>Chisholm, Smith Ann M.</au><au>Schroeder, Richard</au><au>Lueder, Gregg T.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Visual Outcomes in Presumed Congenital Foveal Toxoplasmosis</atitle><jtitle>American journal of ophthalmology</jtitle><addtitle>Am J Ophthalmol</addtitle><date>2020-06-01</date><risdate>2020</risdate><volume>214</volume><spage>9</spage><epage>13</epage><pages>9-13</pages><issn>0002-9394</issn><eissn>1879-1891</eissn><abstract>Congenital macular lesions attributed to toxoplasmosis may limit potential visual acuity. The appearance and location of these scars may cause physicians to overlook associated amblyopia. This study reviews the visual outcomes and benefits of amblyopia therapy in children with foveal toxoplasmosis scars.
Retrospective observational case series.
Setting: Single center. Patient Population: Children with presumed foveal toxoplasmosis scars who underwent amblyopia treatment. Main Outcome Measure: Charts were reviewed for amblyopia treatment, fundus photographs, optical coherence tomography (OCT), and visual acuity.
Median age at presentation was 2.8 years and median follow-up was 6.2 years. Occlusion therapy was undertaken in 9 patients. Median duration of occlusion therapy was 1.7 years. Six patients improved with occlusion therapy (average 4.6 lines gained on optotype acuity). Final visual acuity ranged from 20/25 to 20/250, with 6 of 8 patients better than 20/80. OCT confirmed macular scars in 5 patients, with varying degrees of foveal architecture disruption.
Despite the striking appearance of the lesions in patients with presumed foveal toxoplasmosis, visual potential may be better than expected. The appearance of the lesions is not always predictive of visual outcome. A trial of occlusion therapy to treat amblyopia should be initiated in these patients to ensure that they reach their maximal visual potential.</abstract><cop>United States</cop><pub>Elsevier Inc</pub><pmid>32035830</pmid><doi>10.1016/j.ajo.2020.01.034</doi><tpages>5</tpages></addata></record> |
fulltext | fulltext |
identifier | ISSN: 0002-9394 |
ispartof | American journal of ophthalmology, 2020-06, Vol.214, p.9-13 |
issn | 0002-9394 1879-1891 |
language | eng |
recordid | cdi_proquest_miscellaneous_2353007757 |
source | Access via ScienceDirect (Elsevier) |
subjects | Age Antibiotics Children & youth Congenital diseases Patients Strabismus Surgery Toxoplasmosis Visual impairment |
title | Visual Outcomes in Presumed Congenital Foveal Toxoplasmosis |
url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-23T20%3A28%3A35IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Visual%20Outcomes%20in%20Presumed%20Congenital%20Foveal%20Toxoplasmosis&rft.jtitle=American%20journal%20of%20ophthalmology&rft.au=Reynolds,%20Margaret%20M.M.&rft.date=2020-06-01&rft.volume=214&rft.spage=9&rft.epage=13&rft.pages=9-13&rft.issn=0002-9394&rft.eissn=1879-1891&rft_id=info:doi/10.1016/j.ajo.2020.01.034&rft_dat=%3Cproquest_cross%3E2353007757%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2425684938&rft_id=info:pmid/32035830&rft_els_id=S0002939420300520&rfr_iscdi=true |